Amylyx Pharmaceuticals Plunges as ALS Drug Trial Fails, Raising Questions on FDA Approval
Amylyx Pharmaceuticals experiences a significant drop in its stock value after its drug for amyotrophic lateral sclerosis (ALS) failed to demonstrate benefits for patients in
